Harrow Health, Inc. Stock News

Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.

The Undercovered Dozen spotlights 12 lesser-known stocks and funds with compelling investment theses and recent developments. This week's edition covers articles published between Nov. 28 and Dec. 4, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.

Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Ophthalmology Day (Virtual) Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37 th ...

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and i...

Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Kni...

Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding marke...